Evidence map›Paper›PMID 21513770›Full record

ArticleNeuroscience letters2011

Methylmercury-induced IL-6 release requires phospholipase C activities.

Jason Y Chang

Abstract read
In one paragraph

Article in Neuroscience letters, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Vascular Dysfunction Induced by Mercury Exposure.International journal of molecular sciences · 2019
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Jason Y ChangDepartment of Neurobiology and Developmental Sciences, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA. changjasony@uams.edu
University of Arkansas for Medical Sciences · US

Funding

NEUROSCIENCE RESEARCH CENTER CORE FACILITY AT UAMSP30NS047546 · NINDS · UNIV OF ARKANSAS FOR MED SCIS · PI ZHANG, JUN-MING · 2004 to 2008
$3.1M
NINDS NIH HHS NS047546NINDS NIH HHS P30 NS047546
6 · The paper itself

Abstract

Methylmercury (MeHg) is a neurotoxin capable of causing severe damage to the CNS, especially in the developing fetus. Glia in the CNS release a number of cytokines that are important for proper CNS development and function. We reported earlier that MeHg could induce interleukin-6 (IL-6) release in primary mouse glia. This finding is significant considering previous reports indicating that sustained IL-6 exposure could be detrimental to cerebellar granule neurons, one of the major cellular targets of MeHg cytotoxicity. By using pharmacological antagonists against phophatidycholine- and phosphoinositol-specific phospholipase C, the current study indicated that phospholipase C activity was necessary for MeHg-induced IL-6 release. Results from pharmacological antagonists further suggested that the calcium signaling initiated by phospholipase C appeared essential for this event. In contrast, protein kinase C activity did not appear to be important. Even though mitogen-activated protein kinases were important for IL-6 release in some experimental systems, these enzymes did not appear to be required for MeHg-induced IL-6 release in glia. Based on these data and those reported by us and others, there is a possibility that MeHg-induced phospholipase C activation initiates a calcium signaling that causes phospholipase A(2) activation. This, in turn, leads to arachidonic acid and lysophosphatidyl choline generation, both of which are potent inducers for IL-6 release.

Indexed as

AnimalsCalcium SignalingEnzyme ActivationEnzyme InhibitorsEnzyme-Linked Immunosorbent AssayInterleukin-6Methylmercury CompoundsMiceMice, Inbred C57BLMitogen-Activated Protein KinasesNeurogliaPhospholipases A2Protein Kinase CProtein Kinase InhibitorsType C PhospholipasesEnzyme InhibitorsInterleukin-6Methylmercury CompoundsMitogen-Activated Protein KinasesPhospholipases A2Protein Kinase CProtein Kinase InhibitorsType C Phospholipases

Identifiers

PMID21513770
PMCPMC3103395
OpenAlexW1972784317

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.